Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628 1629
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18310238 | Niraparib Compositions | Non-Final OA | Merck Sharp & Dohme LLC |
| 19303585 | SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILE | Non-Final OA | Madrigal Pharmaceuticals, Inc. |
| 18042018 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 19210024 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | Final Rejection | CTXT PTY LTD |
| 17283217 | USE OF PDE9 INHIBITORS FOR TREATMENT | Non-Final OA | The Johns Hopkins University |
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Final Rejection | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. |
| 18005245 | LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND | Final Rejection | Eli Lilly and Company |
| 17595446 | DIETARY BUTYRATE AND ITS USES | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18546735 | PHENYLACETIC ACID DERIVATIVE, USE THEREFOR, AND PRODUCTION INTERMEDIATE THEREOF | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18410608 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | Final Rejection | OrphAI Therapeutics Inc. |
| 18528630 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | Final Rejection | Orphai Therapeutics Inc. |
| 18201885 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Sage Therapeutics, Inc. |
| 18209783 | METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISUAL PERFORMANCE | Non-Final OA | Opus Genetics, Inc. |
| 17350427 | SEMIFLUORINATED COMPOUNDS | Non-Final OA | NOVALIQ GMBH |
| 18264183 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | Non-Final OA | PTC Therapeutics, Inc. |
| 18332906 | ORAL LIQUID SUSPENSION OF PAN-RAF KINASE INHIBITOR | Non-Final OA | DAY ONE BIOPHARMACEUTICALS, INC. |
| 18034411 | RIFAXIMIN LIQUID FORMULATIONS FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | Non-Final OA | Bausch Health Ireland Limited |
| 18261959 | IMPROVED TREATMENT FOR GLOBOID CELL LEUKODSYTROPHY OR KRABBE DISEASE | Non-Final OA | Rush University Medical Center |
| 18351192 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | Non-Final OA | Dyve Biosciences, Inc. |
| 18271088 | PULSATILE RELEASE CAFFEINE FORMULATION | Non-Final OA | GALVENTA AG |
| 18270900 | SYSTEM AND METHOD FOR DELIVERING THERAPEUTIC AGENTS TO THE UTERINE CAVITY | Non-Final OA | Gynion, LLC |
| 18332603 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Non-Final OA | REATA PHARMACEUTICALS HOLDINGS, LLC |
| 18256092 | COMPOUNDS FOR INHIBITING INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | Non-Final OA | Lieber Institute, Inc. |
| 18201920 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | Final Rejection | BIAL - PORTELA & CA., S.A. |
| 18201498 | PREFERRED ORAL TESTOSTERONE UNDECANOATE THERAPY TO ACHIEVE TESTOSTERONE REPLACEMENT TREATMENT | Non-Final OA | Marius Pharmaceuticals, Inc. |
| 18033187 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | Non-Final OA | INMED PHARMACEUTICALS INC. |
| 17831862 | Compositions for Regulating Homeostasis of Cortisol and Improving Sleep Quality and Methods of Use and Production Thereof | Final Rejection | Unigen, Inc. |
| 18040040 | NOVEL VDAC1 INHIBITORS | Non-Final OA | ABARCEO AB |
| 17629910 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Non-Final OA | BEIGENE, LTD. |
| 17999826 | FORMULATIONS AND METHODS FOR TREATING ERECTILE DYSFUNCTION | Final Rejection | Strategic Drug Solutions, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy